Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beuzet – page 130

1 845 clinical trials in Beuzet, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beuzet at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Beuzet

Open in trial search

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hypertension

Not recruiting

Study on the Effectiveness of Ethanol in Treating Hypertension in Patients with Uncontrolled High Blood Pressure

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ethanol, Anhydrous
  • Sponsor:Ablative Solutions Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety of TX200-TR101 for Preventing Kidney Transplant Rejection in Patients Receiving a Living Donor Transplant

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TX200-TR101
  • Sponsor:Sangamo Therapeutics France

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Fungal infection

Not recruiting

Study on the Effectiveness and Safety of Olorofim vs. Liposomal Amphotericin B for Patients with Invasive Aspergillosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olorofim
  • Sponsor:F2G Limited

Crohn's disease

Not recruiting

Long-Term Study of Ustekinumab for Patients with Crohn's Disease Who Previously Lost Response to Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ustekinumab
  • Sponsor:Belgian IBD Research and Development

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beuzet

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, evaluating innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Infection Prevention
  • Treatment Efficacy

The research explores the effectiveness of novel treatments in reducing the frequency of herpes episodes over a 12-month period, potentially offering new hope for individuals dealing with recurring outbreaks.

02 Therapeutic Interventions

A controlled evaluation of 2LHERP® treatment examining its impact on patients with frequent herpes outbreaks.

  • Symptom Control
  • Episode Reduction
  • Long-term Management

This placebo-controlled research aims to provide robust evidence regarding treatment effectiveness for recurring facial herpes infections.

03 Clinical Outcomes

Investigation into the management of chronic viral infections through controlled therapeutic intervention.

  • Quality of Life Impact
  • Treatment Response
  • Patient Monitoring

The study specifically targets patients experiencing six or more episodes annually, focusing on reducing outbreak frequency and improving patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.